Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in patients with resectable or borderline resectable pancreatic adenocarcinoma
Published in
Journal for Immunotherapy of Cancer, December 2023
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 04 December 2023.
All research outputs
#22,073,178
of 34,412,533 outputs
Outputs from Journal for Immunotherapy of Cancer
#3,401
of 4,731 outputs
Outputs of similar age
#215,233
of 454,017 outputs
Outputs of similar age from Journal for Immunotherapy of Cancer
#75
of 115 outputs
Altmetric has tracked 34,412,533 research outputs across all sources so far. This one is in the 35th percentile – i.e., 35% of other outputs scored the same or lower than it.
So far Altmetric has tracked 4,731 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 15.3. This one is in the 26th percentile – i.e., 26% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 454,017 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 51% of its contemporaries.
We're also able to compare this research output to 115 others from the same source and published within six weeks on either side of this one. This one is in the 34th percentile – i.e., 34% of its contemporaries scored the same or lower than it.
